Tracy Zimmermann is chief scientific officer of City Therapeutics. She brings over 20 years of experience in drug development, with a focus on genetic medicines, and a proven track record of scaling innovative modalities like gene therapy and RNAi.

Prior to City, Dr. Zimmermann was the chief development officer at Generation Bio, where she led the pharmacology, toxicology and DMPK groups to advance the company’s non-viral gene therapy platform from research into preclinical development for liver and extrahepatic indications. Previously, Dr. Zimmermann spent 15 years at Alnylam Pharmaceuticals in numerous roles within research spanning RNAi platform enablement to early program development. While at Alnylam she contributed to the advancement of ONPATTRO®, GIVLAARI® and AMVUTTRA®.

Dr. Zimmermann began her career at Variagenics, Inc. after completing a National Institutes of Health postdoctoral fellowship at Harvard Medical School/Dana-Farber Cancer Institute. She received a B.S. in biochemistry from Lehigh University and a Ph.D. in chemistry from the University of Colorado Boulder.